The Zacks Analyst Blog Highlights: Broadcom, Amgen, NVIDIA, Bristol-Myers and Restaurant Brands

For Immediate Release

Chicago, IL – June 19, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Broadcom AVGO, Amgen AMGN, NVIDIA NVDA, Bristol-Myers BMY and Restaurant Brands QSR.

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Broadcom, Amgen and NVIDIA

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom, Amgen and NVIDIA. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

Broadcom's shares have underperformed the Zacks Electronics - Semiconductors industry over the past year, gaining +9.1% vs. a +13.4% increase. Broadcom reported mixed second-quarter results, wherein the bottom line surpassed expectations, but the top line missed the same.

Notably, revenues increased on a year over year basis. The Zacks analyst thinks the company is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G. Strong ties with leading OEMs across multiple target markets will help the company to gain key insights into the requirements of customers.

Further, Broadcom is a leading player in the semiconductor market based on its multiple target markets, accretive acquisitions and strong cash flow. However, the company lowered its fiscal 2019 revenues outlook. Further, intensifying competition, integration risks and leveraged balance sheet adds to the woes.

(You can read the full research report on Broadcom here >>>).

Shares of Amgen have gained +4.6% year to date, underperforming the Zacks Biomedical and Genetics industry's increase of +10.2%. The Zacks analyst thinks that while Amgen's newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy products will create pressure on the top line in 2019.

Meanwhile, uptake of key drug Repatha has been slow due to payer restrictions. However, recently launched products including Aimovig, biosimilars and international expansion provide incremental growth opportunities. Amgen is also progressing with its pipeline and the approval of Evenity was a boost.

In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver. Amgen's restructuring plan is making it leaner and more cost efficient.

(You can read the full research report on Amgen here >>>).

NVIDIA's shares have underperformed the Zacks General Semiconductor industry over the past year (down -44.3% vs. -21.5%). The Zacks analyst thinks NVIDIA has been making concerted efforts to strengthen its position in the several emerging markets. Growth across Professional Visualization and Automotive segments is expected to be a key catalyst.

Increasing deal wins for autonomous vehicle development and the solid uptake of AI-based smart cockpit infotainment solutions are a tailwind. Further, the company's latest acquisition of Mellanox is likely to be its main driver as it will fortify its datacenter footprint and lend a competitive edge. Rising traction of GeForce laptops and RTX GPUs in the market is a positive.

However, weakness in the data center business persists to be an overhang. A pause in hyperscale spending and softness in demand from some enterprise clients remain major concerns. Further, CPU shortages are a drag on gaming business.

(You can read the full research report on NVIDIA here >>>).

Other noteworthy reports we are featuring today include Bristol-Myers and Restaurant Brands.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They're also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Bristol-Myers Squibb Company (BMY) : Free Stock Analysis Report
 
Broadcom Inc. (AVGO) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Restaurant Brands International Inc. (QSR) : Free Stock Analysis Report
 
NVIDIA Corporation (NVDA) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research